亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Strategy for Detecting Residual Host Cell Proteins Using Aptamers

技術優勢
Detect all HCP species Decrease cost Reliability
技術應用
Biopharmaceuticals Pharmaceuticals Therapeutics
詳細技術說明
Researchers at the University of California, Santa Barbara propose using aptamers (nucleic acids that are selected for high-affinity binding to target ligands) for the detection of HCPs in recombinant biopharmaceutical products. Specifically, the method uses next generation sequencing (NGS) to identify aptamers for binding to all targets in the mixture in parallel, and uses the aptamer arrays to measure the actual binding simultaneously of all aptamers to all targets in the mixture. Because aptamer generation is not dependent on immune recognition, they have the potential to detect all HCP species without depleting any targets. This strategy works as an “all-in-one” detection process leading to lower costs and increased reliability in targeting the HCPs.
*Abstract
A proposal for the use of aptamers (nucleic acids that are selected for high-affinity binding to target ligands) for the detection of HCPs in recombinant biopharmaceutical products.
*Principal Investigation

Name: James McGivney

Department:


Name: Robert Strouse

Department:


Name: Andrew Csordas

Department:


Name: Hyongsok Soh

Department:


Name: Faye Walker

Department:

其他

Background

Recombinant proteins are typically produced in host cells. Host Cell Proteins (HCPs) are process-related impurities that arise from the host cells during the normal course of recombinant protein production. Removal and clearance of HCPs through a purification process must be demonstrated before product can be released for use in the clinic. HCPs are currently detected using polyclonal antibodies in a sensitive immunoassay format. This process of anti-HCP antibodies is time consuming, expensive, and variable. Therefore, a better HCP detection reagent, one that recognizes all or nearly all potential HCPs, would be highly desirable to give better quantitative meaning to the HCP immunoassay results. 


Additional Technologies by these Inventors


Tech ID/UC Case

29495/2014-310-0


Related Cases

2014-310-0

國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備